Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Erbitux First-Line Studies Face Enrollment Challenges From Avastin

  • News

Executive Summary

ImClone is moving Erbitux development forward with an eye on enrollment

You may also be interested in...



Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products

Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies

Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products

Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies

Erbitux Priced For Late Stage Use, ImClone Says; McKesson Is Sole Distributor

The pricing strategy for the oncologic Erbitux reflects the expectation that the biologic will be used primarily in late stage disease, ImClone CEO Daniel Lynch told analysts during a March 15 conference call

Table

View full table

Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS043568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By